Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a pioneer in the discovery and development of CAR-T cell therapies, organized a call today to provide an update on Celyad’s clinical strategy. Christian Homsy, Chief Executive Officer, and Patrick Jeanmart, Chief Financial Officer, delivered a brief presentation followed by a Q&A session.

Click here to listen to the conference call

Celyad Announces Third Quarter 2017 Business Update

Next News

Celyad Announces Third Quarter 2017 Business Update